Introduction: The outbreak of COVID19 has led to a global health and economic crisis. Although no approved treatment exists to date, vaccine prototypes, antiviral medication, preventive measures, and treatment strategies are studied by scientists and pharmaceutical companies worldwide. The objective of this paper is to examine the COVID19 death cases in South Korea in order to identify the distinct features of the deceased, such as sex, age, underlying medical conditions, which can be targeted when searching for a COVID19 treatment strategy.
Material and Methods: Data regarding sex, age, and underlying conditions of the deceased and current cases was obtained from South Korea’s Centers for Disease Control and the Korean Statistical Information Service (data retrieved on May 21, 2020). The data were examined to identify any trends between the parameters using direct statistical analysis. Personal variables of COVID19 patients were studied, such as their sex, age, and preexisting health conditions. The data were analyzed in terms of possible factors leading to COVID19 complications and resulting in patients' deaths.
Results: As of May 21, 2020, 11142 confirmed cases and 264 deaths were reported in South Korea. Sex has not had an impact on the death rate, but it directly correlates with age. No deaths were reported for cases of individuals under 30 years old, and only five deaths were reported between the ages of 30 and 50. Additionally, 98.5 % of victims suffered from an underlying condition. The primary underlying condition in deceased cases was related to circulatory system disorders. The results of the statistical analysis were further used to devise a classification of COVID19 risk factors. It consists of three categories ranging from low to high-risk levels.
Conclusion: Treatment targeted at patients over 60 years old and with circulatory system disorders can reduce the death rate of COVID19 infected patients in South Korea.
Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019; 17(3): 181-92. PMID: 30531947 DOI: 10.1038/s41579-018-0118-9
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet. 2020; 395(10224): 565-74. PMID: 32007145 DOI: 10.1016/S0140-6736(20)30251-8
Dennehy JJ. Evolutionary ecology of virus emergence. Ann N Y Acad Sci. 2017; 1389(1): 124-46. PMID: 28036113 DOI: 10.1111/nyas.13304
Master PS, Perlman, S. Coronaviridae. In: Knipe DM, Howley PM (eds). Fields Virology: Emerging Viruses. Vol 1. 6th Ed. Lippincott Williams & Wilkins (LWW); 2020.
Flint J, Racaniello VR, Rall GF, Skalka AM. Emergence. In: Flint SJ, Racaniello VR, Rall GF, Skalka AM, Enquist LW (eds). Principles of Virology. Vol 2. 4th Ed. Wiley & Sons; 2015.
Al-Tawig JA, Zumla A, Memish ZA. Travel implications of emerging coronaviruses: SARS and MERS-CoV. Travel Med Infect Dis. 2014; 12(5): 422–8. PMID: 25047726 DOI: 10.1016/j.tmaid.2014.06.007
National Institute of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines [Internet]. 2020 [cited: 1 Jun 2020]. Available from: https://www.covid19treatmentguidelines.nih.gov/.
Lu N, Cheng KW, Qamar N, Huang KC, Johnson JA. Weathering COVID-19 storm: Successful control measures of five Asian countries. Am J Infect Control. 2020; 48(7): 851–2. PMID: 32360746 DOI: 10.1016/j.ajic.2020.04.021
Kraemer MUG, Yang CH, Gutierrez B, Wu CH, Klein B, Pigott DM, et al.. The effect of human mobility and control measures on the COVID-19 epidemic in China. Science 2020; 368(6490): 493-7. PMID: 32213647 DOI: 10.1126/science.abb4218
Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020; 12(4): 372. PMID: 32230900 DOI: 10.3390/v12040372
Gandhi M, Yokoe DS, Havlir DV. Asymptomatic transmission, the Achilles’ heel of current strategies to control Covid-19. N Engl J Med. 2020; 382(22): 2158-60. PMID: 32329972 DOI: 10.1056/NEJMe2009758
South Korea's CDC. Database of COVID-19 [Internet]. 2020 [cited: 1 Jun 2020]. Available from: http://ncov.mohw.go.kr/en/
Noh JW, Yoo KB, Kwon YD, Hong JH, Lee Y, Park K. Effect of information disclosure policy on control of infectious disease: MERS-CoV outbreak in South Korea. Int J Environ Res Public Health. 2020; 17(1): 305. PMID: 31906369 DOI: 10.3390/ijerph17010305
Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020; 323(14): 1406-7. PMID: 32083643 DOI: 10.1001/jama.2020.2565
Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. J Infect. 2020; 80(6): 14-18. PMID: 32171866 DOI: 10.1016/j.jinf.2020.03.005